Page last updated: 2024-12-10

2-(2-methoxyethyl)-9-methyl-N-[3-(4-methyl-1-piperidinyl)propyl]-1-oxo-4-pyrido[3,4-b]indolecarboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

The compound you described, 2-(2-methoxyethyl)-9-methyl-N-[3-(4-methyl-1-piperidinyl)propyl]-1-oxo-4-pyrido[3,4-b]indolecarboxamide, is a complex organic molecule with a very specific chemical structure.

**Here's a breakdown:**

* **Chemical Name:** This name describes the molecule's structure in a very detailed way. It tells us about:
* **2-(2-methoxyethyl):** A substituent group attached to the main molecule at position 2. It contains a methoxy group (CH3O-) linked to an ethyl group (-CH2CH3).
* **9-methyl:** A methyl group (CH3-) attached to the molecule at position 9.
* **N-[3-(4-methyl-1-piperidinyl)propyl]:** This part describes a specific amine group (-NH-) attached to the molecule. The amine is bonded to a propyl chain (-CH2CH2CH3) which itself is attached to a 4-methyl-1-piperidinyl group (a cyclic amine with a methyl substituent).
* **1-oxo-4-pyrido[3,4-b]indolecarboxamide:** This part describes the core structure of the molecule. It's a pyrido[3,4-b]indole (a fused ring system) with a carbonyl group (C=O) at position 1, an amide group (CONH-) at position 4, and a carboxyl group (COOH) attached to position 4.

**Importance for Research:**

While the exact purpose of this specific compound isn't clear from its name alone, it's likely to be a candidate drug molecule or a research tool used in fields like:

* **Pharmacology:** This type of molecule often exhibits biological activity and is a potential candidate for developing drugs for various diseases. The complex structure and specific substituents are likely tailored to interact with specific receptors or enzymes in the body.
* **Medicinal Chemistry:** Researchers use such molecules to study structure-activity relationships. By modifying the structure, they can understand how different functional groups affect the compound's activity, leading to the design of more potent or selective drugs.
* **Biochemistry:** This compound might be used as a tool to investigate the mechanisms of various biological processes. Its interactions with biological systems can provide valuable insights into the workings of cells and organisms.

**To understand the specific importance of this compound, you would need more information:**

* **Research context:** What specific area of research is it used in? What are the target biological pathways or receptors?
* **Published studies:** Are there any scientific publications related to this compound? What are the results of those studies?

Without that additional information, it's difficult to say definitively why this specific compound is important. However, based on its structure and complexity, it's likely to play a role in some area of biomedical research.

Cross-References

ID SourceID
PubMed CID3237701
CHEMBL ID1450949
CHEBI ID116605

Synonyms (20)

Synonym
AKOS001802179
2-(2-methoxyethyl)-9-methyl-n-[3-(4-methylpiperidin-1-yl)propyl]-1-oxo-1h,2h,9h-pyrido[3,4-b]indole-4-carboxamide
MLS000087496 ,
2-(2-methoxyethyl)-9-methyl-n-[3-(4-methylpiperidin-1-yl)propyl]-1-oxo-2,9-dihydro-1h-beta-carboline-4-carboxamide
smr000023719
MLS000876638
HMS1622L16
2-(2-methoxyethyl)-9-methyl-n-[3-(4-methylpiperidin-1-yl)propyl]-1-oxopyrido[3,4-b]indole-4-carboxamide
HMS2449M20
2-(2-methoxyethyl)-9-methyl-n-[3-(4-methyl-1-piperidinyl)propyl]-1-oxo-4-pyrido[3,4-b]indolecarboxamide
1-keto-2-(2-methoxyethyl)-9-methyl-n-[3-(4-methylpiperidino)propyl]-beta-carboline-4-carboxamide
cid_3237701
2-(2-methoxyethyl)-9-methyl-n-[3-(4-methylpiperidin-1-yl)propyl]-1-oxidanylidene-pyrido[3,4-b]indole-4-carboxamide
bdbm38395
CHEMBL1450949
Q27200285
SR-01000122924-1
sr-01000122924
CHEBI:116605
cid 3237701
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
beta-carbolinesAny pyridoindole containing a beta-carboline skeleton and their hydrogenated derivatives
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.79430.044717.8581100.0000AID485294
Chain A, HADH2 proteinHomo sapiens (human)Potency32.46480.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency32.46480.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.18380.177814.390939.8107AID2147
thioredoxin reductaseRattus norvegicus (Norway rat)Potency56.23410.100020.879379.4328AID588456
ClpPBacillus subtilisPotency31.62281.995322.673039.8107AID651965
Smad3Homo sapiens (human)Potency3.54810.00527.809829.0929AID588855
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency35.48130.011212.4002100.0000AID1030
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency19.95260.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.20 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]